The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 (PMID: 7382552).Search in Google Scholar

2. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.10.1016/j.cgh.2011.03.020Search in Google Scholar

3. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46:1387–13911768547210.1002/hep.21827Search in Google Scholar

4. Cortez-Pinto H, Camilo ME, Baptista A, et al. Nonalcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–358.10.1016/S0261-5614(99)80015-6Open DOISearch in Google Scholar

5. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. Diabetes 2011;60:2011-7.2178857810.2337/db11-0231314207021788578Search in Google Scholar

6. Reilly ML, Schillie SF, Smith E, et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. J Diabetes Sci Technol 2012;6:858–866.10.1177/193229681200600417344015722920812Open DOISearch in Google Scholar

7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285.10.1111/j.1365-2036.2011.04724.x21623852Search in Google Scholar

8. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889.10.1111/j.1365-2036.2007.03246.x17402991Search in Google Scholar

9. Tellez-Avila FI, Sanchez-Avila F, Garcia-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-477510.3748/wjg.14.4771273933818720537Open DOISearch in Google Scholar

10. Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. (2017) Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study.2835083910.1371/journal.pone.0174291536977828350839Search in Google Scholar

11. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. AmJ Med 2007; 120: 829-834.10.1016/j.amjmed.2007.03.02517904449Search in Google Scholar

12. Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004; 16: 1095-110510.1097/00042737-200411000-0000315489566Open DOISearch in Google Scholar

13. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. AmJ Gastroenterol 2006; 101: 70-7510.1111/j.1572-0241.2005.00307.x16405536Search in Google Scholar

14. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-172510.1053/gast.2002.3657212404245Search in Google Scholar

15. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. AmJ Gastroenterol 2006; 101: 70-75.10.1111/j.1572-0241.2005.00307.xSearch in Google Scholar

16. Giovanni Targher1, Amedeo Lonardo2, Christopher D. Byrne et al. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus, doi: 10.1038/nrendo.2017.173.10.1038/nrendo.2017.17329286050Open DOISearch in Google Scholar

17. Mark CC Cheah, Arthur J McCullough and George Boon-Bee Goh. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017 Sep 28; 5(3): 261–271.Search in Google Scholar

18. Haixia Liu, Jing Fu Ruixia Hong et al. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. PLoS One. 2015; 10(7): e0127782.10.1371/journal.pone.0127782448918326131717Search in Google Scholar

19. Adams LA, Waters OR, Knuiman MW, et al. NAFLDas a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. AmJ Gastroenterol 2009;104:861-7.10.1038/ajg.2009.6719293782Search in Google Scholar

20. Xiong G L, Gadde K M. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med 2014;126:110-6.10.3810/pgm.2014.03.274624685974Open DOISearch in Google Scholar

21. Brashier DB, Sharma AK, Dahiya N, et al. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother 2014;5:175-8.10.4103/0976-500X.130158400892524799830Search in Google Scholar

22. Caixàs A, Albert L, Capel I, et al. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014;8:1419-27.10.2147/DDDT.S55587417404625258511Search in Google Scholar

23. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010;33:284-6.10.2337/dc09-0148Open DOISearch in Google Scholar

24. Horlander J, Kwo P, Cummings O. Atorvastatin for the treatment of NASH (Abstract). Gastroenterol 2001;5:A- 544.10.1016/S0016-5085(08)82704-7Search in Google Scholar

25. Arun J. Sanyal, M.D. et al, Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, N Engl J Med. 2010 May 6; 362(18): 1675–1685. doi:10.1056/NEJMoa 0907929.10.1056/NEJMoa0907929292847120427778Open DOISearch in Google Scholar